Breaking the amyotrophic lateral sclerosis early diagnostic barrier: the promise of general markers

Yizhou Lu , Lu He , Huanyu Meng , Sheng Chen , Qinming Zhou

Exploration of Neuroprotective Therapy ›› 2023, Vol. 3 ›› Issue (6) : 497 -512.

PDF (2293KB)
Exploration of Neuroprotective Therapy ›› 2023, Vol. 3 ›› Issue (6) :497 -512. DOI: 10.37349/ent.2023.00065
Review
research-article
Breaking the amyotrophic lateral sclerosis early diagnostic barrier: the promise of general markers
Author information +
History +
PDF (2293KB)

Abstract

Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease that is associated with selective and progressive loss of motor neurons. As a consequence, the symptoms of ALS are muscle cramps and weakness, and it eventually leads to death. The general markers for early diagnosis can assist ALS patients in receiving early intervention and prolonging their survival. Recently, some novel approaches or previously suggested methods have validated the potential for early diagnosis of ALS. The purpose of this review is to summarize the status of current general markers discovery and development for early diagnosis of ALS, including genes, proteins neuroimaging, neurophysiology, neuroultrasound, and machine learning models. The main genetic markers evaluated are superoxide dismutase 1 (SOD1), chromosome 9 open reading frame 72 (C9orf72), transactivation-responsive DNA binding protein 43 (TARDBP), and fused in sarcoma (FUS) genes. Among proteins, neurofilament light chain is still the most established disease-specific adaptive change in ALS. The expression of chitinases, glial fibrillary acidic protein (GFAP), and inflammatory factors are changed in the early stage of ALS. Besides, more patient-friendly and accessible feature assays are explored by the development of neuroimaging, neurophysiology, and neuroultrasound techniques. The novel disease-specific changes exhibited the promising potential for early diagnosis of ALS. All of these general markers still have limitations in the early diagnosis, therefore there is an urgent need for the validation and development of new disease-specific features for ALS.

Keywords

Amyotrophic lateral sclerosis / marker / genes / neurofilament / magnetic resonance imaging / positron emission tomography / neurophysiology / neuroultrasound

Cite this article

Download citation ▾
Yizhou Lu, Lu He, Huanyu Meng, Sheng Chen, Qinming Zhou. Breaking the amyotrophic lateral sclerosis early diagnostic barrier: the promise of general markers. Exploration of Neuroprotective Therapy, 2023, 3 (6) : 497-512 DOI:10.37349/ent.2023.00065

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Zhou Q, He L, Hu J, Gao Y, Shen D, Ni Y, et al. Increased expression of coronin-1a in amyotrophic lateral sclerosis: a potential diagnostic biomarker and therapeutic target. Front Med. 2022; 16: 723-35.

[2]

Zhou QM, Zhang JJ, Li S, Chen S, Le WD. n-butylidenephthalide treatment prolongs life span and attenuates motor neuron loss in SOD1G93A mouse model of amyotrophic lateral sclerosis. CNS Neurosci Ther. 2017; 23: 375-85.

[3]

Talbott EO, Malek AM, Lacomis D. The epidemiology of amyotrophic lateral sclerosis. In: Aminoff MJ, Boller F, Swaab DF, editors. Handbook of Clinical Neurology. Amsterdam: Elsevier; 2016. pp. 225-38.

[4]

van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet. 2017; 390: 2084-98.

[5]

Spencer PS, Palmer VS, Kisby GE. Cycad β- N-methylamino-L-alanine (BMAA), methylazoxymethanol, genotoxicity, and neurodegeneration. Toxicon. 2018; 155: 49-50.

[6]

Cox PA, Kostrzewa RM, Guillemin GJ. BMAA and neurodegenerative illness. Neurotox Res. 2018; 33: 178-83.

[7]

Pablo J, Banack SA, Cox PA, Johnson TE, Papapetropoulos S, Bradley WG, et al. Cyanobacterial neurotoxin BMAA in ALS and Alzheimer’s disease. Acta Neurol Scand. 2009; 120: 216-25.

[8]

Ra D, Sa B, Sl B, Js M, Sj M, DA D, et al. Is exposure to BMAA a risk factor for neurodegenerative diseases? A response to a critical review of the BMAA hypothesis. Neurotox Res. 2021; 39: 81-106.

[9]

Spencer PS, Nunn PB, Hugon J, Ludolph AC, Ross SM, Roy DN, et al. Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. Science. 1987; 237: 517-22.

[10]

Montine TJ, Li K, Perl DP, Galasko D. Lack of β-methylamino-l-alanine in brain from controls, AD, or Chamorros with PDC. Neurology. 2005; 65: 768-9.

[11]

Cruz-Aguado R, Winkler D, Shaw CA. Lack of behavioral and neuropathological effects of dietary β-methylamino-L-alanine (BMAA) in mice. Pharmacol Biochem Behav. 2006; 84: 294-9.

[12]

de Munck E, Muñoz-Sáez E, Miguel BG, Solas MT, Ojeda I, Martínez A, et al. β-N-methylamino-L-alanine causes neurological and pathological phenotypes mimicking Amyotrophic Lateral Sclerosis (ALS): the first step towards an experimental model for sporadic ALS. Environ Toxicol Pharmacol. 2013; 36: 243-55.

[13]

Scott L, Downing T. Dose-dependent adult neurodegeneration in a rat model after neonatal exposure to β-N-methylamino-L-alanine. Neurotox Res. 2019; 35: 711-23.

[14]

Yin HZ, Yu S, Hsu CI, Liu J, Acab A, Wu R, et al. Intrathecal infusion of BMAA induces selective motor neuron damage and astrogliosis in the ventral horn of the spinal cord. Exp Neurol. 2014; 261: 1-9.

[15]

Martin RM, Bereman MS, Marsden KC. BMAA and MCLR interact to modulate behavior and exacerbate molecular changes related to neurodegeneration in larval zebrafish. Toxicol Sci. 2021; 179: 251-61.

[16]

Sini P, Dang TBC, Fais M, Galioto M, Padedda BM, Lugliè A, et al. Cyanobacteria, cyanotoxins, and neurodegenerative diseases: dangerous liaisons . Int J Mol Sci. 2021; 22: 8726.

[17]

Berntzon L, Ronnevi LO, Bergman B, Eriksson J. Detection of BMAA in the human central nervous system. Neuroscience. 2015; 292: 137-47.

[18]

Brooks BW, Lazorchak JM, Howard MD, Johnson MV, Morton SL, Perkins DA, et al. Are harmful algal blooms becoming the greatest inland water quality threat to public health and aquatic ecosystems? Environ Toxicol Chem. 2016; 35: 6-13.

[19]

Xu X, Shen D, Gao Y, Zhou Q, Ni Y, Meng H, et al. A perspective on therapies for amyotrophic lateral sclerosis: Can disease progression be curbed? Transl Neurodegener. 2021; 10: 29.

[20]

Brooks BR, Miller RG, Swash M, Munsat TL ; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000; 1: 293-9.

[21]

Feldman EL, Goutman SA, Petri S, Mazzini L, Savelieff MG, Shaw PJ, et al. Amyotrophic lateral sclerosis. Lancet. 2022; 400: 1363-80.

[22]

Costa J, Swash M, de Carvalho M. Awaji criteria for the diagnosis of amyotrophic lateral sclerosis: a systematic review. Arch Neurol. 2012; 69: 1410-6.

[23]

Hannaford A, Pavey N, van den Bos M, Geevasinga N, Menon P, Shefner JM, et al. Diagnostic utility of Gold Coast criteria in amyotrophic lateral sclerosis. Ann Neurol. 2021; 89: 979-86.

[24]

Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016; 539: 197-206.

[25]

Mead RJ, Shan N, Reiser HJ, Marshall F, Shaw PJ. Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nat Rev Drug Discov. 2023; 22: 185-212.

[26]

van Rheenen W, van der Spek RAA, Bakker MK, van Vugt JJFA, Hop PJ, Zwamborn RAJ, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet. 2021; 53: 1636-48.

[27]

Deng HX, Hentati A, Tainer JA, Iqbal Z, Cayabyab A, Hung WY, et al. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science. 1993; 261: 1047-51.

[28]

Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993; 362: 59-62.

[29]

Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017; 3: 17071.

[30]

Kaur SJ, McKeown SR, Rashid S. Mutant SOD1 mediated pathogenesis of Amyotrophic Lateral Sclerosis. Gene. 2016; 577: 109-18.

[31]

Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994; 264: 1772-5.

[32]

Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 1995; 14: 1105-16.

[33]

Smith RA, Miller TM, Yamanaka K, Monia BP, Condon TP, Hung G, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest. 2006; 116: 2290-6.

[34]

Borel F, Gernoux G, Sun H, Stock R, Blackwood M, Brown RH Jr, et al. Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. Sci Transl Med. 2018; 10: eaau6414.

[35]

Miller TM, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013; 12: 435-42.

[36]

Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020; 383: 109-19.

[37]

Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, et al.; VALOR and OLE Working Group. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022; 387: 1099-110.

[38]

Mendez EF, Sattler R. Biomarker development for C9orf72 repeat expansion in ALS. Brain Res. 2015; 1607: 26-35.

[39]

Ciura S, Lattante S, Le Ber I, Latouche M, Tostivint H, Brice A, et al. Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann Neurol. 2013; 74: 180-7.

[40]

Almeida S, Gascon E, Tran H, Chou HJ, Gendron TF, Degroot S, et al. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol. 2013; 126: 385-99.

[41]

Donnelly CJ, Zhang PW, Pham JT, Haeusler AR, Mistry NA, Vidensky S, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013; 80: 415-28.

[42]

Gendron TF, Belzil VV, Zhang YJ, Petrucelli L. Mechanisms of toxicity in C9FTLD/ALS. Acta Neuropathol. 2014; 127: 359-76.

[43]

Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, Dejesus-Hernandez M, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013; 77: 639-46.

[44]

Lagier-Tourenne C, Baughn M, Rigo F, Sun S, Liu P, Li HR, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A. 2013; 110: E4530-9.

[45]

Zu T, Liu Y, Bañez-Coronel M, Reid T, Pletnikova O, Lewis J, et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A. 2013; 110: E4968-77.

[46]

Shi Y, Lin S, Staats KA, Li Y, Chang WH, Hung ST, et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat Med. 2018; 24: 313-25.

[47]

Kumar V, Hasan GM, Hassan MI. Unraveling the role of RNA mediated toxicity of C9orf72 repeats in C9-FTD/ALS. Front Neurosci. 2017; 11: 711.

[48]

Kanekura K, Yagi T, Cammack AJ, Mahadevan J, Kuroda M, Harms MB, et al. Poly-dipeptides encoded by the C9ORF72 repeats block global protein translation. Hum Mol Genet. 2016; 25: 1803-13.

[49]

Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang YJ, Prudencio M, et al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci Transl Med. 2017; 9: eaai7866.

[50]

Meeter LHH, Gendron TF, Sias AC, Jiskoot LC, Russo SP, Donker Kaat L, et al. Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. Ann Clin Transl Neurol. 2018; 5: 583-97.

[51]

Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M, Kayikci M, et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci. 2011; 14: 452-8.

[52]

Deshaies JE, Shkreta L, Moszczynski AJ, Sidibé H, Semmler S, Fouillen A, et al. TDP-43 regulates the alternative splicing of hnRNP A1 to yield an aggregation-prone variant in amyotrophic lateral sclerosis. Brain. 2018; 141: 1320-33.

[53]

Neelagandan N, Gonnella G, Dang S, Janiesch PC, Miller KK, Küchler K, et al. TDP-43 enhances translation of specific mRNAs linked to neurodegenerative disease. Nucleic Acids Res. 2019; 47: 341-61.

[54]

Kawahara Y, Mieda-Sato A. TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proc Natl Acad Sci U S A. 2012; 109: 3347-52.

[55]

Kim G, Gautier O, Tassoni-Tsuchida E, Ma XR, Gitler AD. ALS genetics: gains, losses, and implications for future therapies. Neuron. 2020; 108: 822-42.

[56]

Zou ZY, Zhou ZR, Che CH, Liu CY, He RL, Huang HP. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017; 88: 540-9.

[57]

Chiò A, Borghero G, Pugliatti M, Ticca A, Calvo A, Moglia C, et al.; Italian Amyotrophic Lateral Sclerosis Genetic (ITALSGEN) Consortium. Large proportion of amyotrophic lateral sclerosis cases in Sardinia due to a single founder mutation of the TARDBP gene. Arch Neurol. 2011; 68: 594-8.

[58]

Korobeynikov VA, Lyashchenko AK, Blanco-Redondo B, Jafar-Nejad P, Shneider NA. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat Med. 2022; 28: 104-16.

[59]

Fang T, Je G, Pacut P, Keyhanian K, Gao J, Ghasemi M. Gene therapy in amyotrophic lateral sclerosis. Cells. 2022; 11: 2066.

[60]

Wang L, Yi F, Fu L, Yang J, Wang S, Wang Z, et al. CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs. Protein Cell. 2017; 8: 365-78.

[61]

Bhinge A, Namboori SC, Zhang X, VanDongen AMJ, Stanton LW. Genetic correction of SOD1 mutant iPSCs reveals ERK and JNK activated AP1 as a driver of neurodegeneration in amyotrophic lateral sclerosis. Stem Cell Reports. 2017; 8: 856-69.

[62]

Guo W, Naujock M, Fumagalli L, Vandoorne T, Baatsen P, Boon R, et al. HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat Commun. 2017; 8: 861.

[63]

Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019; 90: 870-81.

[64]

Skillbäck T, Mattsson N, Blennow K, Zetterberg H. Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. Amyotroph Lateral Scler Frontotemporal Degener. 2017; 18: 397-403.

[65]

Brodovitch A, Boucraut J, Delmont E, Parlanti A, Grapperon AM, Attarian S, et al. Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS. Sci Rep. 2021; 11: 703.

[66]

van der Ende EL, Bron EE, Poos JM, Jiskoot LC, Panman JL, Papma JM, et al.; GENFI consortium. A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain. 2022; 145: 1805-17.

[67]

Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018; 84: 130-9.

[68]

Behzadi A, Pujol-Calderón F, Tjust AE, Wuolikainen A, Höglund K, Forsberg K, et al. Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics. Sci Rep. 2021; 11: 22128.

[69]

Boylan KB, Glass JD, Crook JE, Yang C, Thomas CS, Desaro P, et al. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2013; 84: 467-72.

[70]

Benatar M, Wuu J, Lombardi V, Jeromin A, Bowser R, Andersen PM, et al. Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Frontotemporal Degener. 2019; 20: 538-48.

[71]

Gaur N, Perner C, Witte OW, Grosskreutz J. The chitinases as biomarkers for amyotrophic lateral sclerosis: signals from the CNS and beyond. Front Neurol. 2020; 11: 377.

[72]

Varghese AM, Sharma A, Mishra P, Vijayalakshmi K, Harsha HC, Sathyaprabha TN, et al. Chitotriosidase - a putative biomarker for sporadic amyotrophic lateral sclerosis. Clin Proteomics. 2013; 10: 19.

[73]

Oeckl P, Weydt P, Steinacker P, Anderl-Straub S, Nordin F, Volk AE, et al.; German Consortium for Frontotemporal Lobar Degeneration. Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. J Neurol Neurosurg Psychiatry. 2019; 90: 4-10.

[74]

Thompson AG, Gray E, Bampton A, Raciborska D, Talbot K, Turner MR. CSF chitinase proteins in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019; 90: 1215-20.

[75]

Gille B, De Schaepdryver M, Dedeene L, Goossens J, Claeys KG, Van Den Bosch L, et al. Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry. 2019; 90: 1338-46.

[76]

Steinacker P, Verde F, Fang L, Feneberg E, Oeckl P, Roeber S, et al.; FTLDc study group. Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. J Neurol Neurosurg Psychiatry. 2018; 89: 239-47.

[77]

Steinacker P, Feneberg E, Halbgebauer S, Witzel S, Verde F, Oeckl P, et al. Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. Amyotroph Lateral Scler Frontotemporal Degener. 2021; 22: 276-86.

[78]

Middeldorp J, Hol EM. GFAP in health and disease. Prog Neurobiol. 2011; 93: 421-43.

[79]

Ishiki A, Kamada M, Kawamura Y, Terao C, Shimoda F, Tomita N, et al. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal lobar degeneration. J Neurochem. 2016; 136: 258-61.

[80]

Heller C, Foiani MS, Moore K, Convery R, Bocchetta M, Neason M, et al.; GENFI. Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2020; 91: 263-70.

[81]

Verde F, Milone I, Maranzano A, Colombo E, Torre S, Solca F, et al. Serum levels of glial fibrillary acidic protein in patients with amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2023; 10: 118-29.

[82]

Tanaka M, Toldi J, Vécsei L. Exploring the etiological links behind neurodegenerative diseases: inflammatory cytokines and bioactive kynurenines. Int J Mol Sci. 2020; 21: 2431.

[83]

Hu Y, Cao C, Qin XY, Yu Y, Yuan J, Zhao Y, et al. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study. Sci Rep. 2017; 7: 9094.

[84]

Van Everbroeck B, Dewulf E, Pals P, Lübke U, Martin JJ, Cras P. The role of cytokines, astrocytes, microglia and apoptosis in Creutzfeldt-Jakob disease. Neurobiol Aging. 2002; 23: 59-64.

[85]

Rohrer JD, Nicholas JM, Cash DM, van Swieten J, Dopper E, Jiskoot L, et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol. 2015; 14: 253-62.

[86]

Papma JM, Jiskoot LC, Panman JL, Dopper EG, den Heijer T, Donker Kaat L, et al. Cognition and gray and white matter characteristics of presymptomatic C9orf72 repeat expansion. Neurology. 2017; 89: 1256-64.

[87]

Chiò A, Pagani M, Agosta F, Calvo A, Cistaro A, Filippi M. Neuroimaging in amyotrophic lateral sclerosis: insights into structural and functional changes. Lancet Neurol. 2014; 13: 1228-40.

[88]

Bertrand A, Wen J, Rinaldi D, Houot M, Sayah S, Camuzat A, et al.; Predict to Prevent Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis (PREV-DEMALS) Study Group. Early cognitive, structural, and microstructural changes in presymptomatic C9orf72 carriers younger than 40 years. JAMA Neurol. 2018; 75: 236-45.

[89]

Wen J, Zhang H, Alexander DC, Durrleman S, Routier A, Rinaldi D, et al.; Predict to Prevent Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis (PREV-DEMALS) Study Group. Neurite density is reduced in the presymptomatic phase of C9orf72 disease. J Neurol Neurosurg Psychiatry. 2019; 90: 387-94.

[90]

Lee SE, Sias AC, Mandelli ML, Brown JA, Brown AB, Khazenzon AM, et al. Network degeneration and dysfunction in presymptomatic C9ORF72 expansion carriers. Neuroimage Clin. 2017; 14: 286-97.

[91]

Waugh RE, Danielian LE, Shoukry RFS, Floeter MK. Longitudinal changes in network homogeneity in presymptomatic C9orf72 mutation carriers. Neurobiol Aging. 2021; 99: 1-10.

[92]

Popuri K, Beg MF, Lee H, Balachandar R, Wang L, Sossi V, et al. FDG-PET in presymptomatic C9orf72 mutation carriers. Neuroimage Clin. 2021; 31: 102687.

[93]

Van Weehaeghe D, Ceccarini J, Delva A, Robberecht W, Van Damme P, Van Laere K. Prospective validation of18F-FDG brain PET discriminant analysis methods in the diagnosis of amyotrophic lateral sclerosis. J Nucl Med. 2016; 57: 1238-43.

[94]

Van Laere K, Vanhee A, Verschueren J, De Coster L, Driesen A, Dupont P, et al. Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol. 2014; 71: 553-61.

[95]

D’hulst L, Van Weehaeghe D, Chiò A, Calvo A, Moglia C, Canosa A, et al. Multicenter validation of [18F]-FDG PET and support-vector machine discriminant analysis in automatically classifying patients with amyotrophic lateral sclerosis versus controls. Amyotroph Lateral Scler Frontotemporal Degener. 2018; 19: 570-7.

[96]

Saba L, Viscomi MT, Caioli S, Pignataro A, Bisicchia E, Pieri M, et al. Altered functionality, morphology, and vesicular glutamate transporter expression of cortical motor neurons from a presymptomatic mouse model of amyotrophic lateral sclerosis. Cereb Cortex. 2016; 26: 1512-28.

[97]

Eisen A, Braak H, Del Tredici K, Lemon R, Ludolph AC, Kiernan MC. Cortical influences drive amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2017; 88: 917-24.

[98]

Menon P, Geevasinga N, Yiannikas C, Howells J, Kiernan MC, Vucic S. Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurol. 2015; 14: 478-84.

[99]

Menon P, Kiernan MC, Vucic S. Cortical hyperexcitability precedes lower motor neuron dysfunction in ALS. Clin Neurophysiol. 2015; 126: 803-9.

[100]

Vucic S, Cheah BC, Yiannikas C, Kiernan MC. Cortical excitability distinguishes ALS from mimic disorders. Clin Neurophysiol. 2011; 122: 1860-6.

[101]

Misawa S, Noto Y, Shibuya K, Isose S, Sekiguchi Y, Nasu S, et al. Ultrasonographic detection of fasciculations markedly increases diagnostic sensitivity of ALS. Neurology. 2011; 77: 1532-7.

[102]

Geevasinga N, Howells J, Menon P, van den Bos M, Shibuya K, Matamala JM, et al. Amyotrophic lateral sclerosis diagnostic index: toward a personalized diagnosis of ALS. Neurology. 2019; 92: e536-47.

[103]

Tang M, Gao C, Goutman SA, Kalinin A, Mukherjee B, Guan Y, et al. Model-based and model-free techniques for amyotrophic lateral sclerosis diagnostic prediction and patient clustering. Neuroinformatics. 2019; 17: 407-21.

[104]

Fukushima K, Takamatsu N, Yamamoto Y, Yamazaki H, Yoshida T, Osaki Y, et al. Early diagnosis of amyotrophic lateral sclerosis based on fasciculations in muscle ultrasonography: a machine learning approach. Clin Neurophysiol. 2022; 140: 136-44.

PDF (2293KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉